- Aldeyra Therapeutics Inc (NASDAQ:ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629.
- Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure.
- ADX-629 and placebo were well tolerated, and no safety concerns were noted.
- Related: Aldeyra’s ADX-2191 Aces Late-Stage Study In Rare Vision Disorder.
- In addition to the statistical superiority of ADX-629 over the placebo in Romberg test balance time, flushing, and acetaldehyde, total cholesterol, and LDL levels were statistically lower following ADX-629 treatment than following placebo treatment.
- Aldeyra plans to initiate a Phase 2 trial of ADX-629 in moderate alcoholic hepatitis in 2023. Results from a Phase 2 trial of ADX-629 in chronic cough are expected in 1H of 2023, and results from Phase 2 clinical trials of ADX-629 in minimal change disease and Sjögren-Larsson Syndrome are expected in 2023.
- Price Action: ALDX shares are up 0.96% at $6.28 on the last check Tuesday.
- Photo Via Company
Related Posts
Raymond James Downgrades Retail Opportunity to Market Perform
Raymond James analyst RJ Milligan downgrades Retail Opportunity (NASDAQ:ROIC) from Outperform to Market Perform.
Baking Soda Maker Church & Dwight Beats Q2 Consensus, Boasts Strong Consumer Demand
Church & Dwight Co Inc (NYSE: CHD) reported second-quarter (Q2) 2023 sales growth of 9.7% year-on-year to $1.45 billion,
Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside is expected from the accelerating iAccess and iPRIME launches.